Table 5.
Hemolytic potential of selected peptides in canine RBCs.
| ID | Peptide | Safe concentration (nM) | Hemolytic (yes/no) |
|---|---|---|---|
| P1 | PCI-H1-004 | < 200 | No |
| P2 | PCI-H1-030 | < 200 | No |
| P3 | PCII-H1-008 | < 200 | No |
| P4 | PCI-F3-053 | < 200 | No |
| P5 | PCII-F3-012 | < 200 | No |
| P6 | PCI-IEDB-H1 | < 200 | No |
| P7 | LINB-IEDB-H | < 200 | No |
| P8 | PCI-F3-054 | < 200 | No |
| P9 | PCII-IEDB-H2 | < 200 | No |
| P10 | PCI-IEDB-F1 | < 200 | No |
| P11 | PCII-IEDB-F2 | < 25 | No |
| P12 | LINB-IEDB-F | < 200 | No |
PBS was used as a negative hemolytic control, and 0.1% Triton X-100® was used as a positive hemolytic control. Two independent experiments with 4 replicates (n = 8) were carried out. The percent hemolysis was calculated as the relationship between the treatment and control absorbance, and a safe concentration was reported.